Eli Lilly and Company launched Humalog mix 75/25 kwikpen and Humalog Junior kwikpen for diabetic ketoacidosis treatment market
The growing prevalence of diabetes and diabetic ketoacidosis is fostering the growth of the diabetic ketoacidosis treatment market. According to the U.S National Library of Health, the frequency of diabetic ketoacidosis in adults with type1 diabetes is high, and approximately one-third of the adults have severe conditions such as diabetes type-1 and diabetic ketoacidosis. Additionally, healthcare providers are focused on spreading awareness regarding diabetes type 1 and diabetic ketoacidosis which is again fostering the growth of the diabetic ketoacidosis treatment market. For instance, in April 2020, Diabetes UK, a healthcare and research charity association in England, stated that the National Health Services should be kept open for emergency conditions such as diabetic ketoacidosis as they may lead to life-threatening situation. In August 2020, Eli Lilly and Company (United States) added two non-branded insulin products Humalog mix 75/25 kwikpen and Humalog Junior kwikpen at...